558 related articles for article (PubMed ID: 15026200)
1. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
3. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Mungall BA; Xu X; Klimov A
Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
[TBL] [Abstract][Full Text] [Related]
5. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
Hurt AC; McKimm-Breschkin JL; McDonald M; Barr IG; Komadina N; Hampson AW
Virus Res; 2004 Jul; 103(1-2):205-11. PubMed ID: 15163511
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
7. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.
Cheam AL; Barr IG; Hampson AW; Mosse J; Hurt AC
Antiviral Res; 2004 Sep; 63(3):177-81. PubMed ID: 15451185
[TBL] [Abstract][Full Text] [Related]
8. A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
Hurt AC; Barr IG; Komadina N; Hampson AW
Virus Res; 2004 Jul; 103(1-2):79-83. PubMed ID: 15163493
[TBL] [Abstract][Full Text] [Related]
9. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
[TBL] [Abstract][Full Text] [Related]
10. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
[TBL] [Abstract][Full Text] [Related]
11. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.
Buxton RC; Edwards B; Juo RR; Voyta JC; Tisdale M; Bethell RC
Anal Biochem; 2000 May; 280(2):291-300. PubMed ID: 10790313
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
McSharry JJ; McDonough AC; Olson BA; Drusano GL
Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
[TBL] [Abstract][Full Text] [Related]
13. [Critical review of anti-influenza drugs].
van Loon FP; Voordouw AC; Simonian S; Koopmans PP
Ned Tijdschr Geneeskd; 2000 Jan; 144(4):165-7. PubMed ID: 10668542
[TBL] [Abstract][Full Text] [Related]
14. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
Hayden F; Klimov A; Tashiro M; Hay A; Monto A; McKimm-Breschkin J; Macken C; Hampson A; Webster RG; Amyard M; Zambon M
Antivir Ther; 2005; 10(8):873-7. PubMed ID: 16430192
[TBL] [Abstract][Full Text] [Related]
15. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.
McKimm-Breschkin J; Trivedi T; Hampson A; Hay A; Klimov A; Tashiro M; Hayden F; Zambon M
Antimicrob Agents Chemother; 2003 Jul; 47(7):2264-72. PubMed ID: 12821478
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
[TBL] [Abstract][Full Text] [Related]
17. Neuraminidase inhibitors in the management of influenza--experience of an outpatient practice.
Vogel GE
Med Microbiol Immunol; 2002 Dec; 191(3-4):161-3. PubMed ID: 12458352
[TBL] [Abstract][Full Text] [Related]
18. Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005.
Ferraris O; Kessler N; Valette M; Lina B
Vaccine; 2006 Nov; 24(44-46):6656-9. PubMed ID: 16797804
[TBL] [Abstract][Full Text] [Related]
19. Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.
Wutzler P; Kossow KD; Lode H; Ruf BR; Scholz H; Vogel GE;
J Clin Virol; 2004 Oct; 31(2):84-91. PubMed ID: 15364262
[TBL] [Abstract][Full Text] [Related]
20. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
Wang D; Sleeman K; Huang W; Nguyen HT; Levine M; Cheng Y; Li X; Tan M; Xing X; Xu X; Klimov AI; Gubareva LV; Shu Y
Antiviral Res; 2013 Mar; 97(3):240-4. PubMed ID: 23267831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
